Active substance
Calcipotriol
- SFDA 2
- US FDA 12
- Health Canada 1
- US price lines 5
- NHS prices 1
- WHO EML 1
- Safety 6
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DAIVONEX CREAM 50MCG-G | 0.005 % | Cream · Topical | 1 Tube | SAR 45.55 | NCE · Prescription | Leo Pharma | Valid |
| DAIVONEX OINT. 50MCG-G | 0.005 µg | Ointment · Topical | 1 Tube | SAR 35.35 | NCE · Prescription | Leo Pharma | Valid |
Indications — CHI Daman Drug Formulary
PSORIASIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DOVONEX | 0.005% | ointment · topical | LEO PHARMA AS | Prescription | 29 Dec 1993 |
| DOVONEX | 0.005% | cream · topical | LEO PHARMA AS | Prescription | 22 Jul 1996 |
| CALCIPOTRIENE | 0.005% | solution · topical | FOUGERA PHARMS | Prescription | 6 May 2008 |
| CALCIPOTRIENE | 0.005% | ointment · topical | GLENMARK PHARMS | Prescription | 24 Mar 2010 |
| SORILUX | 0.005% | aerosol, foam · topical | MAYNE PHARMA | Prescription | 6 Oct 2010 |
| CALCIPOTRIENE | 0.005% | solution · topical | COSETTE PHARMS NC | Prescription | 24 Mar 2011 |
| CALCIPOTRIENE | 0.005% | cream · topical | GLENMARK SPECLT | Prescription | 9 Jun 2015 |
| CALCIPOTRIENE | 0.005% | solution · topical | CHARTWELL RX | Prescription | 26 Dec 2017 |
| DOVONEX | 0.005% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution · topical | LEO PHARM | Discontinued | 3 Mar 1997 |
| CALCIPOTRIENE | 0.005% | solution · topical | HIKMA PHARMS | Discontinued | 19 Nov 2009 |
| CALCIPOTRIENE | 0.005% | solution · topical | CHARTWELL RX | Discontinued | 20 Nov 2009 |
| CALCIPOTRIENE | 0.005% | cream · topical | CHARTWELL RX | Discontinued | 30 May 2012 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| DOVONEX | 01976133 | 50 MCG / G | OINTMENT · TOPICAL | LEO PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CALCIPOTRIENE 0.005% CREAM | $1.05567 | per GM | 23 Sep 2026 |
| US NADAC | CALCIPOTRIENE 0.005% CREAM | $1.04341 | per GM | 23 Sep 2026 |
| US NADAC | CALCIPOTRIENE 0.005% OINTMENT | $2.08437 | per GM | 23 Sep 2026 |
| US NADAC | CALCIPOTRIENE 0.005% OINTMENT | $2.3377 | per GM | 23 Sep 2026 |
| US NADAC | CALCIPOTRIENE 0.005% SOLUTION | $2.71166 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Calcipotriol 50micrograms/g ointment | £8.56 | 30 gram | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 13.4. Dermatological medicines > Medicines affecting skin differentiation and proliferation · core
Psoriasis of unspecified type
Local > Topical > Cream: 50 µg per mL (0.005%) | Local > Topical > Lotion: 50 µg per mL (0.005%) | Local > Topical > Ointment: 50 µg per mL (0.005%)
Safety signals and safety-related labeling changes
- US FDA 3 Oct 2025 DOVONEX — safety-related labeling change
Labeling sections changed: Adverse Reactions - US FDA 3 Oct 2025 DOVONEX — safety-related labeling change
Labeling sections changed: Adverse Reactions - US FDA 16 Oct 2020 ENSTILAR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 5 Nov 2019 SORILUX — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 25 Jul 2019 TACLONEX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Dec 2018 TACLONEX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Calcipotriol
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.